Publications by authors named "Andrew Natenshon"

Article Synopsis
  • A phase 1 trial tested the safety and immune response of an mRNA-based vaccine, mRNA-1647, for cytomegalovirus (CMV) in both seronegative and seropositive adults.
  • 154 participants were involved, with most reporting mild to moderate adverse reactions and no serious side effects noted.
  • The results indicated that mRNA-1647 was safe and effective in stimulating both antibody and cell-mediated immune responses in participants.
View Article and Find Full Text PDF

Cytomegalovirus (CMV) infection during pregnancy may result in long-term health problems for children with congenital CMV (cCMV). Currently, no prevention or treatment interventions are approved by the Food and Drug Administration for a cCMV indication. Healthcare provider and public awareness is low, and formal clinical practice guidelines and local practice patterns vary.

View Article and Find Full Text PDF

Objective: Cytomegalovirus (CMV) can infect individuals at any age, including infants, who may contract it from infected mothers (congenital CMV [cCMV]). Whereas CMV infection is typically asymptomatic or causes mild illness in healthy individuals, infection can result in severe outcomes in immunocompromised individuals and in infants with cCMV. This systematic review aims to characterize the economic impact of CMV and cCMV infections.

View Article and Find Full Text PDF

Objective: Cytomegalovirus (CMV) infection is typically asymptomatic in healthy individuals; however, certain populations are vulnerable to infection and may develop serious sequelae. CMV infection may also have a broad impact on humanistic outcomes, including patient health status and quality of life (QoL). We conducted a systematic literature review (SLR) to describe the global humanistic burden of CMV and congenital CMV (cCMV) infections across all age groups.

View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) is a common pathogen that affects individuals of all ages and establishes lifelong latency. Although CMV is typically asymptomatic in healthy individuals, infection during pregnancy or in immunocompromised individuals can cause severe disease. Currently, treatments are limited, with no prophylactic vaccine available.

View Article and Find Full Text PDF